Skip to main content
Figure 5 | Journal for ImmunoTherapy of Cancer

Figure 5

From: Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

Figure 5

α-PD-L1 mAb treatment coupled with doxorubicin treatment does not enhance survival over α-PD-L1 mAb treatment alone. Survival of combinational treatment of metastatic osteosarcoma with doxorubicin and α-PD-L1 mAb was significantly higher than chemotherapy treated alone group, p = 0.0026, although no significant difference in survival was seen between combinational α-PD-L1 mAb and doxorubicin treatment and α-PD-L1 mAb alone. N = 10 for all treatment groups.

Back to article page